Skip to main content

Advertisement

SpringerLink
Log in

Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

To verify the expression of type 1 insulin-like growth factor receptor (IGF-IR) and its impact on hematopoietic cells apoptosis in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), marrow samples from 16 patients with MDS and 16 patients with AML were examined along with 16 healthy donors as controls. Immunocytochemical methods (alkaline phosphatase anti-alkaline phosphatase) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (fluorescence) were used simultaneously on nucleated cell cytospins. The ratio of IGF-IR positive cells and apoptotic cells as well as the relationship between them were then analyzed separately. A quantitative real-time reverse transcriptase–polymerase chain reaction (PCR) was administrated for six MDS cases and two normal controls to validate IGF-IR expression detected by immunochemistry. In our assay, IGF-IR appeared to have higher to lower expression rate in turn from AML (86.8±13.8%) to MDS (56.8±14.3%) and then to normal controls (40.4±9.6%) (P<0.01 between each group). In MDS nucleated cells, IGF-IR showed stronger expression in refractory anemia with excess blasts (RAEB)/RAEB in transformation/chronic myelomonocytic leukemia subgroup when compared to RA/RA with ringed sideroblasts cases (64.1±3.2 vs 53.5±16.2%) (P>0.05). Nucleated cells from MDS marrow underwent more apoptosis (5.4±3.0%) than that in normal marrow (1.2±0.9%) (P<0.01) and AML marrow (0.3±0.4%) (also, P<0.01 between each compared group). For both AML and MDS cases, apoptotic signals presented mainly in individual IGF-IR negative cells (9.0±4.8%) and less so in IGF-IR positive cells (1.4±2.4%) (P<0.01). When analyzed by groups, cell number with IGF-IR expression showed a negative correlation to apoptotic cells amount (r=−0.852; P<0.01) but positive correlation to their blast count (r=0.677; P<0.01). Outcome from real-time quantitative PCR appeared to have a trend of enhanced IGF-IR expression in advanced MDS subtypes. In conclusion, overexpression of IGF-IR existed in hematopoietic cells in MDS and AML marrows, which appeared to be contributed to disease progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574–5581

    Article  PubMed  CAS  Google Scholar 

  2. Wu Y, Tewari M, Cui S et al (1996) Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol 168:499–509

    Article  PubMed  CAS  Google Scholar 

  3. Coppola D, Saunders B, Fu L et al (1999) The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 59:3264–3270

    PubMed  CAS  Google Scholar 

  4. Poulaki V, Mitsiades CS, Kotoula V et al (2002) Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 161:643–654

    PubMed  CAS  Google Scholar 

  5. Yee D, Rosen N, Favone RE et al (1991) The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat Res 53:93–106

    PubMed  CAS  Google Scholar 

  6. Singleton JR, Randolph AE, Feldman EL (1996) Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56:4522–4529

    PubMed  CAS  Google Scholar 

  7. Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589–6597

    Article  PubMed  CAS  Google Scholar 

  8. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113(2):316–328

    Article  PubMed  CAS  Google Scholar 

  9. Camirand A, Zakikhani M, Young F, Pollak M (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7(4):R570–R579

    Article  PubMed  CAS  Google Scholar 

  10. Raza A, Mundle S, Iftikhar A, et al (1995) Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143–154

    Article  PubMed  CAS  Google Scholar 

  11. Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24(6):954–958, 960, 962

    PubMed  CAS  Google Scholar 

  12. Shimon I, Shpilberg O (1995) The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19:233–240

    Article  PubMed  CAS  Google Scholar 

  13. Zumkeller W, Burdach S (1999) The insulin-like growth factor system in normal and malignant hematopoietic cells. Blood 94:3653–3657

    PubMed  CAS  Google Scholar 

  14. Baier TG, Ludwig WD, Schonberg D, Hartman KK (1992) Characterisation of insulin-like growth factor I receptors of human acute lymphoblastic leukaemia (ALL) cell lines and primary ALL cells. Eur J Cancer 28A(6–7):1105–1110

    Article  PubMed  CAS  Google Scholar 

  15. Schillaci R, GaleanoA, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF (2005) Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol 130(1):58–66

    Article  PubMed  CAS  Google Scholar 

  16. He Q, Li X, Tao Y, Liu YZ, Yang LP, Ying SX (2005) Expression of insulin-like growth factor receptor type I in marrow nucleated cells from hematologic malignancies and its anti-apoptotic effect. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13(3):483–487

    PubMed  Google Scholar 

  17. Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, Dantzer R, Kelley KW (1997) Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138(1):362–368

    Article  PubMed  CAS  Google Scholar 

  18. Kellerer M, Obermaier-Kusser B, Ermel B, Wallner U, Haring HU, Petrides PE (1990) An altered IGF-I receptor is present in human leukemic cells. J Biol Chem 265(16):9340–9345

    PubMed  CAS  Google Scholar 

  19. Valverde AM, Mur C, Brownlee M, Bentio M (2004) Susceptibility to apoptosis in insulin-like factor-I receptor-deficient brown adipocytes. Mol Biol Cell 15(11):5101–5117

    Article  PubMed  CAS  Google Scholar 

  20. Jasty R, Van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P, Opipari A, Feldman E, Castle VP (2001) Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia 3(4):304–313

    Article  PubMed  CAS  Google Scholar 

  21. Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27(1):27–35

    Article  PubMed  CAS  Google Scholar 

  22. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64(23):8620–8629

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are thankful to Dr. H. Joachim Deeg of Fred Hutchinson Cancer Research Center for reviewing the manuscript and for providing helpful comments. This research was supported by a grant from Shanghai Municipal Technology Committee (044119630).

Author information

Authors and Affiliations

  1. Hematology Department, Shanghai Sixth Hospital of Shanghai Jiaotong University, 200233, Shanghai, PR China

    He Qi, Li Xiao, Wu Lingyun, Tao Ying, Liu Yi-Zhi, Ying Shao-Xu & Pu Quan

Authors
  1. He Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wu Lingyun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liu Yi-Zhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ying Shao-Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pu Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Xiao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qi, H., Xiao, L., Lingyun, W. et al. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis. Ann Hematol 85, 95–101 (2006). https://doi.org/10.1007/s00277-005-0031-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-0031-y

Keywords

Search

Navigation